Previous close | 1.5900 |
Open | 1.6950 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.6950 - 1.6950 |
52-week range | 1.5150 - 2.8690 |
Volume | |
Avg. volume | 8,075 |
Market cap | 8.444B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 16.95 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.06 (3.69%) |
Ex-dividend date | 31 Jul 2023 |
1y target est | N/A |
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).